このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Catalyst Pharmaceuticals マネジメント

マネジメント基準チェック /24

Catalyst Pharmaceuticals'の CEO はRich Dalyで、 Jan2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.2%を直接所有しており、その価値は$ 3.52M 。経営陣と取締役会の平均在任期間はそれぞれ3.5年と11.5年です。

主要情報

Rich Daly

最高経営責任者

US$14.1m

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.2%
経営陣の平均在職期間	3.5yrs
取締役会の平均在任期間	11.5yrs

経営陣の近況

Recent updates

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

CEO（最高経営責任者

Rich Daly (63 yo)

less than a year

在職期間

US$14,076,923

報酬

Mr. Richard John Daly, also known as Rich, MBA, had been an Independent Director at Catalyst Pharmaceuticals, Inc. from February 2015 until January 1, 2024 and serves as its Chief Executive Officer and Dir...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Richard John Daly	President	less than a year	US$14.08m	0.20% $ 3.6m
Steven Miller	Executive VP	14.8yrs	US$3.40m	0.70% $ 12.6m
Gary Ingenito	Chief Medical & Regulatory Officer	9.1yrs	US$2.37m	0.044% $ 786.8k
Jeffrey Del Carmen	Executive VP & Chief Commercial Officer	4.1yrs	US$2.51m	0.016% $ 282.1k
Michael Kalb	Executive VP	less than a year	データなし	データなし
Mary Coleman	VP & Head of Investor Relations	2.9yrs	データなし	データなし
Brian Elsbernd	Chief Compliance Officer & Chief Legal Officer	8.4yrs	US$353.27k	0.11% $ 1.9m
Pete Curry	Vice President of Sales	4.1yrs	データなし	データなし
Stanley Iyadurai	Senior Vice President of Medical Affairs & Drug Discovery	1.3yrs	データなし	データなし
Preethi Sundaram	Chief Strategy Officer	3yrs	US$1.70m	0.022% $ 391.0k
Philip Schwartz	Corporate Secretary	no data	データなし	データなし

3.5yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: CPRXの経営陣は経験豊富であると考えられます ( 3.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Richard John Daly	President	9.4yrs	US$14.08m	0.20% $ 3.6m
David Tierney	Independent Director	21.8yrs	US$370.99k	0.30% $ 5.3m
Patrick McEnany	Co-Founder & Chairman	22.5yrs	US$2.15m	3.83% $ 69.3m
Donald Denkhaus	Independent Director	9.4yrs	US$376.24k	0.37% $ 6.7m
Charles O'Keeffe	Lead Independent Director	19.6yrs	US$397.24k	0.58% $ 10.5m
Eugene Laska	Member of Scientific Advisory Board	no data	データなし	データなし
Robert Fechtner	Member of Scientific Advisory Board	no data	データなし	データなし
Jonathan Brodie	Chairman of Scientific Advisory Board	no data	データなし	データなし
Molly Harper	Independent Director	3.1yrs	US$363.12k	0% $ 0
Richard Silverman	Member of Scientific Advisory Board	13.7yrs	データなし	データなし
Tamar Thompson	Independent Director	1.2yrs	US$610.43k	データなし

11.5yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: CPRXの取締役会は経験豊富で経験豊富です ( 11.5年の平均在任期間)。

Catalyst Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Insider recently sold US$411k worth of stock

Co-Founder exercised options to buy US$4.3m worth of stock.

COO & Chief Scientific Officer recently sold US$570k worth of stock

Recent updates

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment deteriorates as stock falls 30%

Investor sentiment improved over the past week

Chief Medical & Regulatory Officer exercised options and sold US$100k worth of stock

Chief Accounting Officer recently sold US$2.0m worth of stock

Independent Director recently sold US$332k worth of stock

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Price target increased to US$18.10

Price target increased to US$18.10

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Price target increased to US$17.30

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Catalyst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse(R) Expanding Patient Population to Include Pediatric Patients

Chief Accounting Officer recently sold US$714k worth of stock

マネジメント基準チェック /24